The Future of Antibody Therapeutics:
4 Trends Every Biotech Leader Needs to Know
Antibody therapeutics remain the cornerstone of modern biologics, and Europe is rapidly emerging as a hub for next-generation innovation. From AI-enabled discovery to cutting-edge bispecifics and agile manufacturing, the future of antibody engineering is being built today. This concise trend report outlines the four most critical developments shaping the space in 2024 – along with the strategic questions leaders must ask to remain competitive.
Trend 1: AI and Machine Learning – Beyond Discovery
Artificial Intelligence (AI) and Machine Learning (ML) are no longer just buzzwords – they are core to antibody R&D success. Companies are now applying these technologies not only to hit discovery but also to predict developability, immunogenicity, and optimal biophysical properties.
Example
UK-based LabGenius raised £35 million in May 2024 to advance its ML-powered platform for antibody optimisation and to move assets toward clinical development. Their approach combines robotic experimentation with Bayesian optimisation.
Trend 2: The Rise of Bispecific and Multispecific Antibodies
Bispecifics and multispecifics are becoming standard tools, especially in oncology and autoimmune indications. Companies are innovating not only on targets but also on formats – engineering conditionally active antibodies, trispecific constructs, and modular plug-and-play platforms.
Example
In June 2024, Genmab reported promising Phase 2 results for its bispecific antibody acasunlimab (DuoBody-PD-L1x4-1BB) in NSCLC patients, showing signs of durable activity and favourable safety. Originally developed in collaboration with BioNTech, Genmab has now taken full control of the programme.
Trend 3: ADCs 2.0 – Precision, Potency, and Progress
Antibody-Drug Conjugates (ADCs) are experiencing a renaissance, with novel payloads, stable linkers, and site-specific conjugation technologies enhancing their therapeutic index. Europe is producing both innovation and manufacturing strength in this space.
Example 1
Heidelberg Pharma (Germany) presented encouraging data in March 2024 from its Phase I trial of HDP-101, its first-in-class ADC using Amanitin as payload.
Example 2
AstraZeneca and Daiichi Sankyo’s Enhertu received expanded EMA approvals in 2024, solidifying its role in breast and lung cancer care in Europe.
Trend 4: Flexible & Decentralised Manufacturing Models
The complexity of modern antibody formats is driving new paradigms in biomanufacturing – modular sites, single-use systems, and smart QA/QC automation are becoming essential. Europe is responding with record investments in scalable, future-ready facilities.
Example 1
Samsung Biologics signed two major manufacturing deals in 2024 with European pharmaceutical partners, worth over $668 million, including ADC production capabilities.
Example 2
Evotec will open its J.POD Toulouse facility in late 2024 to serve the EU market with agile, modular biomanufacturing.
Example 3
Sanofi announced a €1 billion investment in May 2024 to double monoclonal antibody production at its Vitry-sur-Seine site.
Conclusion: Agility Defines Leadership
Whether you're developing the next blockbuster or enabling platform-based partner programmes, agility – in discovery, format design, and manufacturing – is the new competitive edge. These trends are already redefining Europe’s antibody landscape. The time to reassess your strategy is now.
Join us at Antibody & TIDES 2025, for the Antibody Engineering programme to meet the pioneers, learn from real-world case studies, and future-proof your R&D pipeline.